Projected Earnings Date: 2024-08-09    (Delayed quote data   2025-04-03)
Last
 2.90
Change
 ⇓ -0.09   (-3.01%)
Volume
  282,037
Open
 2.76
High
 3.01
Low
 2.76
8EMA (Daily)
 3.03
40EMA (Daily)
 3.08
50EMA (Daily)
 3.10
STO (Daily)
 37.724
MACD Hist (Daily)
 -0.047
8EMA (Weekly)
 3.038
40EMA (Weekly)
 3.30
50EMA (Weekly)
 3.37
STO (Weekly)
 29.472
MACD Hist (Weekly)
 -0.020
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com